Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 1_Prevention of chemotherapy drug-mediated human hair follicle damage: combined use of cooling with antioxidant suppresses oxidative stress and prevents matrix keratinocyte c... by Khalidah Ibraheem (9525220)

“…This combinatorial approach holds translational promise for improving the efficacy and consistency of scalp cooling in preventing CIA, ultimately improving cancer patient quality-of-life during chemotherapy treatment.…”

Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 2_Prevention of chemotherapy drug-mediated human hair follicle damage: combined use of cooling with antioxidant suppresses oxidative stress and prevents matrix keratinocyte c... by Khalidah Ibraheem (9525220)

“…This combinatorial approach holds translational promise for improving the efficacy and consistency of scalp cooling in preventing CIA, ultimately improving cancer patient quality-of-life during chemotherapy treatment.…”

Table 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 3_Prevention of chemotherapy drug-mediated human hair follicle damage: combined use of cooling with antioxidant suppresses oxidative stress and prevents matrix keratinocyte c... by Khalidah Ibraheem (9525220)

“…This combinatorial approach holds translational promise for improving the efficacy and consistency of scalp cooling in preventing CIA, ultimately improving cancer patient quality-of-life during chemotherapy treatment.…”

Mitigating toxicity of arsenic in sunflower (<i>Helianthus annuus</i> L.) with phosphate rock and farmyard manure using contrasting soil textures by Muhammad Awais Piracha (21234904)

“…<p>Arsenic (As) immobilization in soil using inorganic/organic amendments may improve the productivity of As<b>-</b>contaminated soils. …”

Supplementary file 3_Efficacy of Xiaoyao-san preparations in treating Hashimoto’s thyroiditis: a meta-analysis and systematic review.docx by Chengna Wang (21535973)

“…Subgroup analysis indicated XY significantly improved FT3 and FT4 levels, but XYS preparations combined with LT4 did not enhance FT3/FT4 restoration. …”

Supplementary file 2_Efficacy of Xiaoyao-san preparations in treating Hashimoto’s thyroiditis: a meta-analysis and systematic review.zip by Chengna Wang (21535973)

“…Subgroup analysis indicated XY significantly improved FT3 and FT4 levels, but XYS preparations combined with LT4 did not enhance FT3/FT4 restoration. …”

Supplementary file 1_Association of antenatal dexamethasone administration timing with outcomes in preterm infants in a low- and middle-income country.docx by Vijay Kalrao (22696397)

“…No other secondary outcomes differed significantly.</p>Conclusion<p>Dexamethasone administration within 24 h before delivery did not reduce mortality but significantly decreased the risk of severe NEC. …”

Supplementary file 1_Efficacy of Xiaoyao-san preparations in treating Hashimoto’s thyroiditis: a meta-analysis and systematic review.zip by Chengna Wang (21535973)

“…Subgroup analysis indicated XY significantly improved FT3 and FT4 levels, but XYS preparations combined with LT4 did not enhance FT3/FT4 restoration. …”

Supplementary file 1_Efficacy and safety of the commercial Chinese polyherbal preparation Liu Shen Wan as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a sy... by Yajing Li (1394572)

“…Meta-analysis demonstrated that LSW plus conventional treatment significantly outperformed conventional treatment alone in shortening vesicle cessation time [MD = −1.44, 95% CI (−1.66, −0.93), p < 0.00001, I² = 70%], accelerating scab formation (MD = −1.72, 95% CI (−2.09, −1.35), p < 0.00001, I² = 38%), reducing scab shedding time (MD = −2.22, 95% CI (−3.64, −0.80), p = 0.002, I² = 36%), decreasing time to pain resolution (MD = −2.46, 95% CI (−3.52, −1.39), p < 0.00001, I² = 0%), and shortening pain persistence duration (MD = −1.97, 95% CI (−2.49, −1.46), p < 0.00001, I² = 86%). …”

Supplementary file 2_Efficacy and safety of the commercial Chinese polyherbal preparation Liu Shen Wan as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a sy... by Yajing Li (1394572)

“…Meta-analysis demonstrated that LSW plus conventional treatment significantly outperformed conventional treatment alone in shortening vesicle cessation time [MD = −1.44, 95% CI (−1.66, −0.93), p < 0.00001, I² = 70%], accelerating scab formation (MD = −1.72, 95% CI (−2.09, −1.35), p < 0.00001, I² = 38%), reducing scab shedding time (MD = −2.22, 95% CI (−3.64, −0.80), p = 0.002, I² = 36%), decreasing time to pain resolution (MD = −2.46, 95% CI (−3.52, −1.39), p < 0.00001, I² = 0%), and shortening pain persistence duration (MD = −1.97, 95% CI (−2.49, −1.46), p < 0.00001, I² = 86%). …”

Data Sheet 1_Efficacy and safety of the commercial Chinese polyherbal preparation Liu Shen Wan as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a systematic... by Yajing Li (1394572)

“…Meta-analysis demonstrated that LSW plus conventional treatment significantly outperformed conventional treatment alone in shortening vesicle cessation time [MD = −1.44, 95% CI (−1.66, −0.93), p < 0.00001, I² = 70%], accelerating scab formation (MD = −1.72, 95% CI (−2.09, −1.35), p < 0.00001, I² = 38%), reducing scab shedding time (MD = −2.22, 95% CI (−3.64, −0.80), p = 0.002, I² = 36%), decreasing time to pain resolution (MD = −2.46, 95% CI (−3.52, −1.39), p < 0.00001, I² = 0%), and shortening pain persistence duration (MD = −1.97, 95% CI (−2.49, −1.46), p < 0.00001, I² = 86%). …”